<DOC>
	<DOCNO>NCT00041665</DOCNO>
	<brief_summary>Radiotherapy high dose chemotherapy bone marrow transplantation peripheral blood stem cell transplantation frequently use treatment patient cancer bone marrow lymph node Hodgkin 's disease , non-Hodgkin 's lymphoma , leukemia multiple myeloma . A common side effect radiotherapy high dose chemotherapy mucositis ( inflammation inside mouth throat result pain difficulty swallow ) . Mucositis often severe patient receive intravenous nutrition pain medication hospital . In study , investigational recombinant human growth factor call Keratinocyte Growth Factor ( rHuKGF ) evaluate determine protective effect mucosal tissue ability reduce mouth throat soreness .</brief_summary>
	<brief_title>Recombinant Human Keratinocyte Growth Factor Reduce Oral Mucositis Hematologic Malignancy Patients Undergoing Peripheral Blood Stem Cell Transplantation After Radiation High-dose Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Stomatitis</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>* Patients : nonHodgkin 's lymphoma , Hodgkin 's disease , acute myelogenous leukemia , acute lymphoblastic leukemia , chronic myelogenous leukemia , chronic lymphocytic leukemia , multiple myeloma * Eligible fractionate total body irradiation ( fTBI ) plus highdose chemotherapy follow autologous PBPC support . * 18 year age old * Karnofsky performance status great equal 70 % * Minimum 1.5 Mio CD34+ cells/kg cryopreserved transplanted * Informed consent participation study * History , concurrent cancer NHL , Hodgkin 's disease , AML , ALL , CML , CLL , multiple myeloma * Prior bone marrow peripheral blood stem cell transplantation * Purged stem cell product * Currently active infection oral mucositis * Congestive heart failure * Serum creatinine &gt; 1.5x ULN * Direct bilirubin &gt; 1.5x ULN * Transaminases &gt; 3x ULN * Corrected DLCO &lt; 50 % predict * Subject currently enrol , yet complete least 30 day since end investigational device drug trial ( ) receive investigational agent ( ) . * Subject pregnant ( eg , positive human chorionic gonadotropin [ HCG ] test ) breastfeeding . * Subject refuse use adequate contraceptive precaution . * Known hypersensitivity product administer dosing , include E coliderived product . * Inability give truly informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>